Page 694 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 48 Drug Hypersensitivity 667

28. Sancho-Serra M, Simarro M, Castells M. Rapid IgE desensitization is 41. Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and
antigen specific and impairs early and late mast cell responses targeting management of anaphylaxis practice parameter: 2010 update. J Allergy
FcεRI internalization. Eur J Immunol 2011;41:1004–13. Clin Immunol 2010;126:477–80, e1–42.
29. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J 42. Barbaud A. Skin testing and patch testing in non-IgE-mediated drug
Allergy Clin Immunol 2017;140:335–48. allergy. Curr Allergy Asthma Rep 2014;14:442–8.
30. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to 43. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis
cisplatin: a case report. Gynecol Oncol 1994;53:121–2. of drug hypersensitivity. Allergy 2004;59:809–20.
31. Wong JT, Ling M, Patil S, et al. Oxaliplatin hypersensitivity: evaluation, 44. Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin
implications of skin testing, and desensitization. J Allergy Clin Immunol and a cephalosporin with the same side chain. J Allergy Clin Immunol
Pract 2014;2:40–5. 1996;98:671–7.
32. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the 45. Brockow K, Romano A, Aberer W, et al. Skin testing in patients with
evidence base: World Allergy Organization anaphylaxis guidelines. World hypersensitivity reactions to iodinated contrast media—a European
Allergy Organ J 2015;8:32. multicenter study. Allergy 2009;64:234–41.
33. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to 46. Hepner DL, Castells MC. Anaphylaxis during the perioperative period.
chemotherapy: outcomes and safety of rapid desensitization in 413 cases. Anesth Analg 2003;97:1381–95.
J Allergy Clin Immunol 2008;122:574–80. 47. Coopman SA, Johnson RA, Platt YR, et al. Cutaneous disease and drug
34. Caiado J, Venemalm L, Pereira-Santos MC, et al. Carboplatin-, reactions in HIV infection. N Engl J Med 1993;328:1670–4.
oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the 48. Naisbitt DJ, Farrell J, Gordon SF, et al. Covalent binding of the nitroso
diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol metabolite of sulfamethoxazole leads to toxicity and major
Pract 2013;1:494–500. histocompatibility complex-restricted antigen presentation. Mol
35. Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to Pharmacol 2002;62:628–37.
guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy 49. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between
Clin Immunol 2016;137:1154–64. sulfonamide antibiotics and sulfonamide nonantibiotics. NEJM
36. Dybendal T, Guttormsen AB, Elsayed S, et al. Screening for mast 2003;349:1628–35.
cell tryptase and serum IgE antibodies in 18 patients with anaphylactic 50. Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene
shock during general anaesthesia. Acta Anaesthesiol Scand 2003;47: overproduction in aspirin-exacerbated respiratory disease is driven by
1211–18. platelet-adherent leukocytes. Blood 2012;119:3790–8.
37. Aster RH. Drug-induced immune thrombocytopenia: an overview of 51. Galvão VR, Castells MC. Hypersensitivity to biological agents—updated
pathogenesis. Semin Hematol 1999;36:2–6. diagnosis, management, and treatment. J Allergy Clin Immunol Pract
38. Arndt PA, Garratty G. The changing spectrum of drug-induced immune 2015;3:175–86.
hemolytic anemia. Semin Hematol 2005;42:137–44. 52. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an
39. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of intradermal skin test to predict for the presence or absence of carboplatin
heparin-induced thrombocytopenia: review and update. Thromb Res hypersensitivity. J Clin Oncol 2003;21:4611–14.
2006;118:165–76. 53. Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to
40. Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy
to mAbs: 105 desensitizations in 23 patients, from evaluation to Clin Immunol 2016;137:1154–1164 e12.
treatment. J Allergy Clin Immunol 2009;124:1259–66.